OakChart

Biomerica Inc

BMRAHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.51+0.03 (2.03%)
2026-11-12 04:08 CET
Market cap
6.94 USD m
Revenue, TTM
4.34 USD m
Net income, TTM
-5.01 USD m
Free cash flow, TTM
-3.96 USD m
EPS diluted, TTM
-1.64
P/E
-
Compare

Price

BMRA against its 20, 50 and 200-day averages
2050200
1.502.002.501.6M3.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BMRAclose 1.5120-day 1.6950-day 2.02200-day 2.011.51

48.6% under the 52-week high of 2.94 on 7 Jan 2026. 52-week low 1.45 on 3 Aug 2026. Last 15 sessions, 20.9% high to low

Volume 0.09× normal · the line is the 50-bar volume average

Profile

BMRA
52-week range, 4% of the way up
1.452.93

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. It focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, North America, Asia, South America, and Middle East. The company was founded in September 1971 and is headquartered in Irvine, CA.

Employees50
IPOMar 17, 1980
Beta0.43
ATR, 14d0.12
Rel volume0.09
Short float0.32%
Insider own17.86%
Inst own2.83%

Snapshot

6 groups

Valuation

Index-
Market Cap6.95M
Enterprise Value6.55M
Income-5.01M
Sales4.34M
Book/sh0.79
Cash/sh0.59
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees50
IPOMar 17, 1980

Ratios

P/E-
Forward P/E-
PEG-
P/S1.60
P/B1.90
P/C2.55
P/FCF-
EV/EBITDA-
EV/Sales1.51
Quick Ratio1.33
Current Ratio1.91
Debt/Eq0.64
LT Debt/Eq0.44
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.64
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y31.53% 23.66%
Sales past 3/5Y-5.87% -9.16%
EPS Y/Y TTM-6.64%
Sales Y/Y TTM-11.20%
EPS Q/Q-46825.00%
Sales Q/Q-8.33%
EarningsOct 16 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own17.86%
Insider Trans13.66%
Inst Own2.83%
Inst Trans20.20%
ROA-67.12%
ROE-113.80%
ROIC-95.70%
Gross Margin0.90%
Oper. Margin-125.22%
Profit Margin-115.49%
SMA20-10.75%
SMA50-25.21%
SMA200-24.92%
Trades-

Technical

Shs Outstand4.60M
Shs Float3.78M
Short Float0.32%
Short Ratio0.17
Short Interest0.01M
52W High2.93 -48.55%
52W Low1.45 4.14%
Volatility9.76% 6.75%
ATR (14)0.12
RSI (14)29.89
Beta0.43
Rel Volume0.09
Avg Volume71.28K
Volume6,749

Performance

Perf Week-12.97%
Perf Month-18.38%
Perf Quarter-6.79%
Perf Half Y-32.89%
Perf YTD-40.08%
Perf Year-40.32%
Perf 3Y-80.13%
Perf 5Y-95.89%
Perf 10Y-89.96%
Recom1.00
Target Price6.25
Prev Close1.48
Price1.51
Change %2.03%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
May 05, 2026InitiatedCCitizensMkt Outperform$9+496.0%
Nov 10, 2020InitiatedCColliers SecuritiesBuy$13+760.9%
Jan 04, 2018InitiatedBB. Riley FBR, Inc.Buy$7.50+396.7%

Peers

Mkt cap
TickerCompanyMkt cap
TRIBTrinity Biotech Plc ADR3.72M
CODXCo-Diagnostics Inc2.64M
QDELQuidelOrtho Corp817.18M
BJDXBluejay Diagnostics Inc3.13M
INBSIntelligent Bio Solutions Inc6.96M
AIDX20/20 Biolabs Inc3.00M
OSUROrasure Technologies Inc245.81M
PRPOPrecipio Inc44.40M
XGNExagen Inc121.98M
IMDXInsight Molecular Diagnostics Inc78.21M

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Gary M. HuffDirectorAug 20 '26Buy1.6031,25050,00051,250Aug 27 05:27 PM
MOATAZEDI DAVIDDirectorAug 26 '26Buy1.6010,00016,00040,625Aug 27 05:26 PM
Chin EricDirectorAug 26 '26Buy1.606,25010,00038,750Aug 27 05:26 PM
BARBIERI ALLENExecutive Vice ChairmanAug 26 '26Buy1.6020,00032,00073,542Aug 27 05:24 PM
Irani Zackary S.Chief Executive OfficerAug 26 '26Buy1.6031,25050,000242,570Aug 27 05:23 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Biomerica Reports First Quarter Fiscal 2027 Financial Results (GlobeNewswire)
  • Biomerica Reports Fiscal 2026 Year-End Financial Results (GlobeNewswire)
  • Biomerica Announces $2.23 Million Financing (GlobeNewswire) +24.27%
  • Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development (GlobeNewswire)
  • Biomerica's inFoods IBS Data Accepted for Presentation at Digestive Disease Week 2026 (GlobeNewswire)
  • Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods IBS, Opening a Scalable Medicare Commercialization Pathway (GlobeNewswire)
  • Biomerica Launches inFoods IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs (GlobeNewswire)
  • Biomerica Reports Third Quarter Fiscal 2026 Financial Results (GlobeNewswire)
  • Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect) from One of the Largest Clinical Laboratory Chains in Europe (GlobeNewswire)
  • Biomerica Receives MHRA Registration for hp+detect, Allowing Commercial Sales in Great Britain (GlobeNewswire)
  • Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods IBS Therapy (GlobeNewswire) -5.09%
  • Vietnam Approves Biomerica's EZ Detect for Nationwide Distribution (GlobeNewswire)
  • Biomerica Reports Second Quarter Fiscal 2026 Financial Results (GlobeNewswire)
  • Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods IBS Test (GlobeNewswire) +10.55%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2024Q32025-04-14-0.480--0.4801.12--
2024Q22025-01-15-0.480--0.4441.64--
2022Q32023-04-14-0.960--0.9791.11--
2022Q22023-01-13-0.960--0.9671.48--
2022Q12022-10-13-1.280--1.2651.64--
2021Q42022-08-29-1.094--1.0945.30--
2021Q32022-04-14-0.080-0.800-0.0657.602.901
2021Q22022-01-13-0.720-0.640-0.7154.651.811
2021Q12021-10-15-0.960-0.960-0.9931.261.901
2020Q42021-08-28-0.960-0.880-0.9721.052.221
2020Q32021-04-14-0.906-0.640-1.2363.631.42-
2020Q22021-01-14-1.040-0.780-1.0111.371.86-
2020Q12020-10-15-1.120-0.640-1.1231.141.202
2019Q42020-09-01-0.320-0.534-0.3412.731.702
2019Q32020-04-14-0.720-0.520-0.7021.181.362
2019Q22020-01-14-0.400-0.640-0.3951.601.691

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2012FY--0.5606.47-
2013FY-0.240--0.2405.12-
2014FY-0.320-0.720-0.3204.964.85
2015FY-1.600--1.6005.14-
2017FY-1.360-1.280-1.3605.565.96
2018FY-2.080-2.000-2.0785.205.39
2019FY-1.866-2.054-1.8416.705.65
2020FY-4.320--4.9947.20-
2021FY-2.880--2.86018.87-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-1.36-2.078-1.841-4.994-2.86-4.036-2.843-2.165-1.295-1.6364
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.626-0.444-0.485-0.6060.001-0.454-0.436-0.373-0.374
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Sales, annual5.5645.2016.6937.19918.8715.3395.4155.3114.4534.34
Period201720182019202020212022202320242025TTM
Sales, quarterly1.8071.6361.1190.7491.381.210.9870.8751.265
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shares, annual1.1111.211.4681.5381.6082.1032.1032.5463.1954.599
Period201720182019202020212022202320242025MRQ
Shares, quarterly2.1032.2922.5462.5462.8152.9483.0293.1954.599
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue4.344.455.315.425.3418.877.206.695.20
Cost of Goods Sold Incl. D&A4.304.094.814.804.8915.896.834.913.91
Gross Profit0.040.360.500.610.452.980.371.781.29
Selling, General and Administrative Excl. Other5.475.685.636.987.677.517.874.183.70
Research and Development0.780.791.021.491.581.812.191.911.68
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-5.43-5.32-5.14-6.37-7.22-4.53-7.50-2.40-2.41
Interest Expense--0.000.000.000.000.000.000.00
Unusual Expense-0.34-1.440.000.000.000.000.000.00-
Net Income Before Taxes-4.98-3.75-4.97-5.94-7.09-4.51-7.43-2.33-2.37
Income Taxes0.030.020.000.040.050.020.010.010.02
Consolidated Net Income-5.01-3.77-4.97-5.98-7.14-4.53-7.45-2.34-2.39
Net Income From Continuing Operations-5.01-3.77-4.97-5.98-7.14-4.53-7.45-2.34-2.39
Net Income-5.01-3.77-4.97-5.98-7.14-4.53-7.45-2.34-2.39
EPS (Recurring)-1.59-1.64-2.16-2.84-4.04-2.86-4.99-1.84-2.08
EPS (Basic, Before Extraordinaries)-1.64-1.30-2.16-2.84-4.04-2.86-4.99-1.84-2.08
EPS (Diluted)-1.64-1.30-2.16-2.84-4.04-2.86-4.99-1.84-2.08
EBITDA-5.03-4.90-4.74-5.99-6.87-3.94-7.12-2.00-2.25
Non-Operating Income (Expense)0.110.130.170.430.130.030.070.070.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.380.380.360.660.941.001.070.150.11
Price To Sales Ratio1.591.561.321.803.632.356.059.833.99
Gross Margin0.908.139.3811.288.3515.785.0926.6224.84
Operating Margin-125.22-119.47-96.72-117.58-135.29-24.03-104.18-35.90-46.39
Net Margin-115.49-84.77-93.64-110.40-133.73-24.01-103.43-34.95-46.01
Shares Outstanding4.603.202.552.102.101.611.541.471.21
Market Capitalization6.946.947.769.7723.0545.0444.9066.7121.77

Income statement, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue1.260.880.991.211.380.751.121.64
Cost of Goods Sold Incl. D&A1.160.951.031.160.960.991.101.20
Gross Profit0.10-0.07-0.040.050.42-0.240.020.44
Selling, General and Administrative Excl. Other1.331.461.251.421.541.321.231.43
Research and Development0.210.200.180.190.210.250.220.26
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.23-1.53-1.30-1.37-1.12-1.56-1.21-0.99
Interest Expense--0.000.000.000.000.000.00
Unusual Expense0.00-0.340.000.000.000.000.000.00
Net Income Before Taxes-1.23-1.14-1.30-1.310.01-1.54-1.17-0.95
Income Taxes0.010.010.010.010.000.01-0.00-0.00
Consolidated Net Income-1.23-1.15-1.31-1.320.00-1.54-1.16-0.95
Net Income From Continuing Operations-1.23-1.15-1.31-1.320.00-1.54-1.16-0.95
Net Income-1.23-1.15-1.31-1.320.00-1.54-1.16-0.95
EPS (Recurring)-0.37-0.45-0.44-0.450.00-0.61-0.48-0.44
EPS (Basic, Before Extraordinaries)-0.37-0.37-0.44-0.450.00-0.61-0.48-0.44
EPS (Diluted)-0.37-0.37-0.44-0.450.00-0.61-0.48-0.44
EBITDA-1.15-1.42-1.19-1.27-1.02-1.46-1.11-0.89
Non-Operating Income (Expense)0.000.06-0.010.061.120.030.040.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.110.070.100.090.110.090.090.12
Price To Sales Ratio1.591.651.451.551.691.462.481.20
Gross Margin8.14-8.11-4.464.2130.72-32.581.7026.71
Operating Margin-97.00-175.20-131.51-113.47-81.01-208.81-108.13-60.70
Net Margin-97.39-130.86-132.93-109.090.14-206.14-103.93-58.07
Shares Outstanding4.603.203.032.952.822.552.552.29
Market Capitalization6.947.386.286.807.977.7614.976.55

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1.312.404.179.725.924.208.640.691.20
Short Term Receivables0.790.730.950.720.771.461.771.450.80
Inventories1.711.492.382.062.423.212.852.152.18
Other Current Assets0.220.260.240.300.320.371.510.200.30
Total Current Assets4.024.887.7312.809.439.2314.774.494.48
Net Property, Plant & Equipment1.950.560.941.251.521.861.990.350.35
Total Investments and Advances0.500.170.170.170.170.170.170.170.17
Long-Term Note Receivable-------0.000.01
Intangible Assets0.210.230.210.170.170.290.170.110.10
Deferred Tax Assets-------0.000.01
Other Assets0.080.110.200.080.100.260.170.130.11
Total Assets6.765.959.2514.4511.3711.8217.265.255.23
Short Term Debt Incl. Current Port. of LT Debt0.730.360.330.300.340.330.210.000.00
Accounts Payable0.380.290.290.340.970.580.991.000.66
Other Current Liabilities1.371.091.591.300.700.390.280.260.24
Total Current Liabilities2.481.742.201.952.011.301.481.260.90
Long Term Debt1.650.100.460.791.041.291.570.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities--------0.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities4.131.842.662.733.052.593.051.260.90
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.030.000.00
Common Equity2.634.116.5911.728.329.2314.193.984.33
Total Shareholders Equity2.634.116.5911.728.329.2314.213.984.33
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity2.634.116.5911.728.329.2314.213.984.33
Total Liabilities & Stockholders Equity6.765.959.2514.4511.3711.8217.265.255.23
Book Value Per Share0.821.613.135.585.186.009.673.293.90
Tangible Book Value Per Share0.761.523.035.505.075.819.553.203.81
Full-Time Employees505464626467453939
Price to Book Ratio1.901.401.481.975.414.2411.525.478.35
Return on Assets-59.43-65.44-50.43-55.29-39.07-51.21-20.79-45.68-28.58
Return on Equity-112.10-92.99-65.28-71.23-51.63-63.53-25.71-57.55-33.22
Return on Invested Capital-88.24-118.26-84.79-57.08-48.39-70.79-14.82-60.11-33.82
Quick Ratio0.931.952.435.523.494.638.071.852.57
Current Ratio1.622.803.516.584.697.1010.003.565.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-5.01-3.77-4.97-5.98-7.14-4.53-7.45-2.34-2.39
Depreciation0.400.420.400.370.350.590.380.400.16
Other Funds (Non Cash)0.010.080.470.621.35-0.143.670.180.18
Funds from Operations-4.60-3.28-4.10-4.98-5.44-4.08-3.40-1.76-2.04
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.65-0.140.26-0.38-0.043.60-1.85-2.54-0.20
Cash from Operating Activities-3.96-3.42-3.84-5.36-5.47-0.48-5.25-4.30-2.24
Capital Expenditures-0.00-0.00-0.04-0.12-0.08-0.17-0.30-0.12-0.17
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.00-0.00-0.04-0.12-0.08-0.17-0.30-0.12-0.17
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock3.151.832.11-0.089.392.391.1112.371.90
Repurchase of Common Pref Stock0.000.000.000.00-0.70-0.08-0.170.000.00
Sale of Common Pref Stock3.151.832.11-0.0810.102.481.2812.371.90
Proceedsfrom Stock Options3.151.832.10-0.0810.012.401.1812.151.78
Issuance or Reduction of Debt, Net0.500.500.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.01
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities3.652.332.11-0.089.392.391.1112.371.91
Exchange Rate Effect-0.01-0.00-0.000.01-0.04-0.03-0.01-0.00-0.01
Net Change in Cash-0.32-1.09-1.77-5.553.801.72-4.447.95-0.52
Free Cash Flow-3.96-3.42-3.84-5.41-5.54-0.54-5.39-4.33-2.35
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.01

Balance sheet, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Cash & Short Term Investments2.731.311.342.543.052.40
Short Term Receivables0.900.790.940.951.210.73
Inventories1.631.711.651.521.471.49
Other Current Assets0.140.220.200.180.170.26
Total Current Assets5.414.024.125.195.904.88
Net Property, Plant & Equipment1.881.950.270.370.470.56
Total Investments and Advances0.500.500.170.170.170.17
Intangible Assets0.200.210.230.220.220.23
Other Assets0.080.080.090.090.100.11
Total Assets8.076.764.886.036.855.95
Short Term Debt Incl. Current Port. of LT Debt0.740.730.190.280.370.36
Accounts Payable1.501.170.730.740.680.67
Other Current Liabilities0.600.570.640.570.650.71
Total Current Liabilities2.842.481.561.601.691.74
Long Term Debt1.591.650.000.000.010.10
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities4.424.131.561.601.701.84
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3.652.633.324.435.164.11
Total Shareholders Equity3.652.633.324.435.164.11
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3.652.633.324.435.164.11
Total Liabilities & Stockholders Equity8.076.764.886.036.855.95
Book Value Per Share0.790.821.091.501.831.61
Tangible Book Value Per Share0.750.761.021.431.751.52
Full-Time Employees-50---54
Price to Book Ratio1.902.181.381.291.441.40
Return on Assets-67.12-59.43-68.12-60.49-49.65-65.44
Return on Equity-113.80-112.10-94.32-84.30-69.61-92.99
Return on Invested Capital-23.54-26.76-39.55-29.760.04-36.72
Quick Ratio1.330.931.592.292.611.95
Current Ratio1.911.622.643.253.482.80

Cash flow, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Net Income-1.23-1.15-1.31-1.320.00-1.54
Depreciation0.080.110.100.100.100.10
Other Funds (Non Cash)0.11-0.250.040.100.180.16
Funds from Operations-1.04-1.28-1.17-1.110.28-1.28
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.240.37-0.080.12-0.550.62
Cash from Operating Activities-0.80-0.91-1.25-0.99-0.27-0.66
Capital Expenditures0.000.02-0.020.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.02-0.020.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.230.370.060.480.920.08
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.230.370.060.480.920.08
Proceedsfrom Stock Options2.230.370.060.480.920.08
Issuance or Reduction of Debt, Net0.000.500.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.09
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.230.870.060.480.92-0.01
Exchange Rate Effect-0.00-0.010.00-0.000.000.01
Net Change in Cash1.43-0.03-1.21-0.510.65-0.66
Free Cash Flow-0.80-0.91-1.25-0.99-0.27-0.66

Revenue breakdown

Clinical Lab2024: 3.18M 2025: 2.73M
Contract Manufacturing2024: 1.07M 2025: 891.00K
Over The Counter2024: 1.05M 2025: 821.00K
Physicians Office2024: 11.00K 2025: 9.00K
Asia2024: 1.72M 2025: 1.41M
Europe2024: 1.30M 2025: 1.12M
Middle East2024: 630.00K 2025: 446.00K
North America2024: 1.66M 2025: 1.47M
South America2024: 8.00K 2025: 15.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.32%0.0M3.8M70.76K
2026-10-150.28%0.0M3.8M70.42K
2026-09-300.82%0.0M3.4M70.15K
2026-09-151.19%0.0M3.1M68.47K
2026-08-311.86%0.1M3.1M64.58K
2026-08-140.69%0.0M2.7M12.18K
2026-07-310.87%0.0M2.7M15.23K
2026-07-150.83%0.0M2.7M17.03K
2026-06-301.24%0.0M2.6M20.57K
2026-06-151.42%0.0M2.6M22.23K
2026-05-293.03%0.1M2.6M22.25K
2026-05-153.47%0.1M2.6M22.66K
2026-04-302.41%0.1M2.6M20.51K
2026-04-152.32%0.1M2.6M20.87K
2026-03-312.86%0.1M2.6M20.41K
2026-03-131.76%0.0M2.6M60.46K
2026-02-272.37%0.1M2.6M60.30K
2026-02-132.82%0.1M2.6M60.43K
2026-01-302.90%0.1M2.6M61.74K
2026-01-153.42%0.1M2.6M131.61K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-16DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-16SEC
2026-10-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-08-31SEC
2026-10-158-KCurrent report2026-10-09SEC
2026-10-07EFFECTEffectiveness filing by commission orderSEC
2026-10-07EFFECTEffectiveness filing by commission orderSEC
2026-09-2810-K/A2026-05-31SEC
2026-09-24S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-24S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-103Initial statement of beneficial ownership of securities2026-08-25SEC
2026-09-083Initial statement of beneficial ownership of securities2026-08-27SEC
2026-08-3110-KAnnual report pursuant to Section 13 or 15(d)2026-05-31SEC
2026-08-28SCHEDULE 13DSEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-268-KCurrent report2026-08-20SEC
2026-06-048-KCurrent report2026-05-29SEC
2026-04-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-02-28SEC
2026-02-27S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-01-284Statement of changes in beneficial ownership of securities2025-12-12SEC
2026-01-1410-QQuarterly report pursuant to Section 13 or 15(d)2025-11-30SEC
2025-12-314Statement of changes in beneficial ownership of securities2025-12-12SEC
2025-12-314Statement of changes in beneficial ownership of securities2025-12-12SEC
2025-12-314Statement of changes in beneficial ownership of securities2025-12-12SEC
2025-12-314Statement of changes in beneficial ownership of securities2025-12-12SEC
2025-12-314Statement of changes in beneficial ownership of securities2025-12-12SEC
2025-12-168-KCurrent report2025-12-12SEC
2025-10-23DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08158.00K500
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HRT FINANCIAL LP0.85%
BlackRock, Inc.0.60%
VANGUARD CAPITAL MANAGEMENT LLC0.47%
GEODE CAPITAL MANAGEMENT, LLC0.42%
JANE STREET GROUP, LLC0.41%
Texas Capital Bank Wealth Management Services Inc0.25%
LPL Financial LLC0.24%
VANGUARD FIDUCIARY TRUST CO0.21%
BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC.0.14%
NewEdge Advisors, LLC0.12%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.47%
Fidelity Extended Market Index Fund0.41%
Fidelity Series Total Market Index Fund0.11%
Fidelity Total Market Index Fund0.06%

OakChart. BMRA. Cached 15 minutes.